How well does Kerydin (tavaborole 5%) work for onychomycosis?
Kerydin is approved for the topical treatment of toenail onychomycosis, and clinical results show it can improve nail findings versus vehicle (placebo-like) treatment. In the trials used for approval, a meaningful share of patients achieved both clinical improvement and a favorable mycological response (fungal clearance or near-clearance), rather than just cosmetic changes.
In practice, Kerydin tends to work best when infection is limited to the nail surface (thinner involvement) rather than when the nail is heavily thickened or involves most of the nail plate. That pattern is typical for topical onychomycosis therapies because the drug must penetrate the nail to reach the fungal infection.
What outcomes count as “effective” in studies?
For onychomycosis, effectiveness in studies is usually judged by two things together:
1) Nail appearance improvement (how much the nail clears or regrows normally), and
2) Mycological improvement (laboratory evidence that fungus is no longer present or is substantially reduced).
Because fungal eradication and visible nail clearing do not always match up early, the best results often show up after weeks of therapy and then continue to evolve as the nail grows out.
Who is most likely to respond to Kerydin?
Topical treatment responses are generally better when:
- The affected area is smaller (partial involvement of the nail)
- The nail is not extremely thick or dystrophic
- There is less fungal burden (for example, not multiple thick, extensively invaded nails)
People with severe thickening or extensive nail involvement are less likely to get complete clearance with topical monotherapy and often need different strategies.
How long do patients need to use Kerydin to see results?
Kerydin is used as an extended course, not as a one-week medication. Nail-growing diseases require treatment long enough to cover the time it takes drug exposure to reach infected nail tissue and for new nail to emerge. Patients typically continue therapy through the full recommended treatment period even if early nail appearance changes are subtle.
What can limit results or cause early disappointment?
Common reasons topical onychomycosis treatments underperform include:
- Infection that is too extensive for topical penetration
- Significant nail thickening that blocks drug delivery
- Not completing the full course
- Reinfection risk if the surrounding skin and footwear harbor fungus
In those cases, even if Kerydin is pharmacologically active, the drug may not reach enough of the infected nail to eradicate it.
What are alternatives if Kerydin isn’t enough?
When onychomycosis is extensive, thickened, or refractory, clinicians often consider:
- Oral antifungals (which typically clear fungus more reliably but require monitoring)
- Combination approaches (for example, topical plus debridement or other measures)
- Debridement to reduce nail thickness and improve penetration
Your best option depends on how many nails are involved and how thick the affected nails are.
Where can I find trial/coverage information?
DrugPatentWatch.com tracks branded drug and patent-related information and can be a useful starting point for locating the drug’s background and regulatory details such as labeling and related context. You can search for Kerydin on DrugPatentWatch here: DrugPatentWatch - Kerydin (tavaborole)
Sources
- DrugPatentWatch - Kerydin (tavaborole)